Home > Press > Kodak Launches New Imaging Agent Product Line for Research Applications
Eastman Kodak Company's Molecular Imaging Systems group announced the introduction of KODAK X-SIGHT Imaging Agents, a novel line of imaging agents for in vivo molecular imaging applications.
Kodak Launches New Imaging Agent Product Line for Research Applications
NEW HAVEN, CT | Posted on February 13th, 2007
Once attached to a molecule and injected into an organism, the X-SIGHT imaging agents will travel to the target ( such as a tumor or plaque ) and illuminate the region of interest when excited by the appropriate wavelength of fluorescent light. X-SIGHT imaging agents are biocompatible and non-cytotoxic, making them safe and translatable for research studies in areas such as oncology, cardiology, diabetes, and inflammation, to name a few. They deliver not only superior brightness, but also enhanced photostability allowing more time for image capture.
This new product line leverages Kodak's 50 years of dye chemistry and nanotechnology expertise, merging world-class dyes with a state-of-the-art nanoparticle construct. X-SIGHT imaging agents are uniquely designed to offer biocompatibility along with superior brightness, providing researchers an incredibly bright and robust platform for safely locating their target of interest in vivo.
Together with Kodak's In-Vivo Imaging Systems, the X-SIGHT Imaging Agent line further expands the breadth of leading-edge solutions offered from Kodak to the research community.
"The launch of X-SIGHT Imaging Agents, is a significant milestone toward offering our customers a complete solution of systems and agents to advance their research," commented Shahram Hejazi, PhD, General Manager of Kodak's Molecular Imaging Systems division. "This introduction strengthens our leadership in the molecular imaging arena as we move forward to bridge the gap between preclinical and clinical applications."
X-SIGHT imaging agents can be readily conjugated to a wide range of targeting molecules, including peptides and antibodies, and their proprietary design can accommodate higher payloads of such targets while allowing for longer circulation time. Furthermore, X-SIGHT imaging agents are available in several distinct fluorescent wavelengths, enabling multi-fluorescent in vivo imaging. While the X-SIGHT imaging agents have been optimized for Kodak's In-Vivo Imaging Systems, they are also compatible with other commercially available systems.
X-SIGHT imaging agents are currently available for preclinical use in the United States and will be launched worldwide in March. Kodak further plans to introduce additional imaging agents throughout the year.
About Kodak’s Molecular Imaging Systems Group
Eastman Kodak Company’s Molecular Imaging Systems group - part of Kodak’s Health Group - develops and markets high performance digital imaging systems, imaging agents, film and accessories for the life science research and drug discovery/development market segments.
For more information, please click here
1-877-747-4357, express code 7.
Outside of the United States, call +1-203-786-5657.
Copyright © Eastman Kodak Company
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Cima NanoTech Announces Commercial Production of its SANTE(R) FS200 Touch Films for Large Format Touch Screens February 19th, 2014
Iran to Hold 2nd Prototype Nanotechnology Products Competition January 21st, 2014
Nanotech Coatings UK Limited Announces Plans to Launch Industrial Nanotech, Inc.’s Next Generation Roofing Product to UK & Ireland Markets in Early 2014 December 16th, 2013
Industrial Nanotech, Inc. Reinvents the Roof Tile - Will Bring Next Generation Roofing Product to Market in Early 2014 December 11th, 2013
Malvern specialist to explore use of Nanoparticle Tracking Analysis for characterizing extracellular vesicles at ISEV 2014 March 11th, 2014
Arrowhead to Present at Barclays Global Healthcare Conference March 11th, 2014
Production of Bioactive Material for Quick Treatment of Bone Damages March 10th, 2014
Production of New Type of Electrochemical Drug Sensors for Cardiovascular Diseases March 10th, 2014
Iran Produces Self-Cleaning Coatings for Textile Industries March 12th, 2014
Detecting Bioterrorism: Is Chemistry Enough? Los Alamos scientist addresses bioaerosol risks and detection March 12th, 2014
Tiny Origami Boxes Hold Big Promise for Hydrogen Energy Storage: Graphene folds itself into programmable "nanocage" for hydrogen storage, beating DOE 2020 goal March 12th, 2014
Thailand's Next Move on Research and Innovation March 11th, 2014
Harry Potter-style invisibility cloaks: A real possibility next Christmas? Forget socks and shaving foam, the big kids of tomorrow want an invisible cloak for Christmas December 19th, 2013
Chicago Awareness Organization First Not-for-Profit to Sponsor Dog Training to Detect Ovarian Cancer Odorants December 12th, 2013
ZEISS Microscopes used to create images for Art Exhibit at Midway Airport: Art of Science: Images from the Institute for Genomic Biology October 25th, 2013
New potential for touch screens found at your fingertips September 17th, 2013